Stock Analysis on Net

AbbVie Inc. (NYSE:ABBV)

Common Stock Valuation Ratios (Price Multiples) 
Quarterly Data

Microsoft Excel

Historical Valuation Ratios (Summary)

AbbVie Inc., historical price multiples (quarterly data)

Microsoft Excel
Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017
Price to earnings (P/E) 19.44 21.64 22.07 27.34 30.62 39.63 40.17 22.60 23.92 14.70 17.82 37.29 23.42 21.71 20.60 17.29 22.09 24.91 35.47
Price to operating profit (P/OP) 14.12 14.57 14.21 12.41 13.12 17.23 16.32 14.42 15.23 9.13 10.82 18.43 13.53 17.93 18.35 12.32 14.01 15.78 19.63
Price to sales (P/S) 4.28 4.76 4.53 3.73 3.80 4.07 4.05 4.10 4.59 3.64 4.22 3.69 2.96 3.56 3.58 4.06 4.60 5.37 6.67
Price to book value (P/BV) 16.76 16.59 16.53 15.20 16.23 14.91 14.18 10.93 11.31 44.74 36.95 22.43 18.89 21.33

Based on: 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31).

Valuation ratio Description The company
P/E ratio The P/E ratio tells analyst how much an investor in common stock pays per dollar of current earnings. AbbVie Inc. P/E ratio decreased from Q4 2021 to Q1 2022 and from Q1 2022 to Q2 2022.
P/OP ratio Because P/E ratio is calculated using net income, the ratio can be sensitive to nonrecurring earnings and capital structure, analysts may use price to operating profit. AbbVie Inc. P/OP ratio increased from Q4 2021 to Q1 2022 but then decreased significantly from Q1 2022 to Q2 2022.
P/S ratio An rationale for the P/S ratio is that sales, as the top line in an income statement, are generally less subject to distortion or manipulation than other fundamentals such as EPS or book value. Sales are also more stable than earnings and never negative. AbbVie Inc. P/S ratio increased from Q4 2021 to Q1 2022 but then decreased significantly from Q1 2022 to Q2 2022.
P/BV ratio The P/BV ratio is interpreted as an indicator of market judgment about the relationship between a company required rate of return and its actual rate of return. AbbVie Inc. P/BV ratio increased from Q4 2021 to Q1 2022 and from Q1 2022 to Q2 2022.

Price to Earnings (P/E)

AbbVie Inc., historical P/E calculation (quarterly data)

Microsoft Excel
Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017
No. shares of common stock outstanding1 1,768,096,495 1,767,110,083 1,768,753,829 1,767,880,465 1,767,175,532 1,766,222,336 1,765,881,690 1,765,473,923 1,764,833,246 1,476,742,215 1,479,156,683 1,478,821,109 1,478,483,838 1,478,332,177 1,475,083,514 1,504,216,327 1,514,272,698 1,586,879,451 1,587,972,655 1,596,429,740 1,594,094,698 1,591,540,513
Selected Financial Data (US$)
Net earnings (loss) attributable to AbbVie Inc. (in millions) 924  4,490  4,044  3,179  766  3,553  36  2,308  (738) 3,010  2,801  1,884  741  2,456  (1,826) 2,747  1,983  2,783  52  1,631  1,915  1,711 
Earnings per share (EPS)2 7.15 7.06 6.53 4.26 3.77 2.92 2.61 4.18 3.94 5.71 5.33 2.20 2.79 3.63 3.86 5.03 4.26 4.02 3.34 0.00 0.00 0.00
Share price1, 3 138.92 152.83 144.03 116.53 115.45 115.75 105.01 94.50 94.29 83.96 94.96 82.08 65.23 78.71 79.41 86.96 94.06 100.17 118.60 93.96 71.22 66.99
Valuation Ratio
P/E ratio4 19.44 21.64 22.07 27.34 30.62 39.63 40.17 22.60 23.92 14.70 17.82 37.29 23.42 21.71 20.60 17.29 22.09 24.91 35.47
Benchmarks
P/E Ratio, Competitors5
Amgen Inc. 20.03 22.23 21.05 21.91 22.56 19.20 18.82 17.25 19.97 17.70 17.07 15.53 14.06 13.30 14.01 55.79 52.69 52.13 64.06
Eli Lilly & Co. 51.05 45.29 40.66 40.07 40.34 28.77 31.95 22.54 25.59 26.56 16.19 13.31 13.84 18.38 39.13 249.24 79.88
Johnson & Johnson 24.98 23.95 20.93 23.98 25.51 28.35 28.92 22.51 25.68 23.06 25.99 24.03 21.50 25.68 23.74 243.48 256.64 271.47 268.10
Merck & Co. Inc. 13.36 15.70 14.78 28.65 34.23 28.00 26.72 17.67 19.70 19.18 20.60 22.67 23.07 23.97 33.46 56.97 132.14 96.71 61.63
Moderna Inc. 5.19 4.21 5.00 16.31 48.08 107.74
Pfizer Inc. 9.56 11.11 11.76 14.03 20.05 20.15 19.62 25.36 14.99 13.04 11.63 12.60 16.12 19.69 21.58 10.64 10.66 9.43 9.99
Regeneron Pharmaceuticals Inc. 11.67 9.15 8.37 9.96 10.38 13.27 15.09 19.91 22.27 28.35 19.86 17.03 15.94 14.56 18.17 21.53 26.96 22.09 28.99
Thermo Fisher Scientific Inc. 31.09 28.15 27.35 29.43 24.63 23.23 27.89 38.43 44.19 35.50 33.36 33.89 31.08 35.11 35.19 36.71 39.27 37.52 37.66

Based on: 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31).

1 Data adjusted for splits and stock dividends.

2 Q2 2022 Calculation
EPS = (Net earnings (loss) attributable to AbbVie Inc.Q2 2022 + Net earnings (loss) attributable to AbbVie Inc.Q1 2022 + Net earnings (loss) attributable to AbbVie Inc.Q4 2021 + Net earnings (loss) attributable to AbbVie Inc.Q3 2021) ÷ No. shares of common stock outstanding
= (924,000,000 + 4,490,000,000 + 4,044,000,000 + 3,179,000,000) ÷ 1,768,096,495 = 7.15

3 Closing price as at the filing date of AbbVie Inc. Quarterly or Annual Report.

4 Q2 2022 Calculation
P/E ratio = Share price ÷ EPS
= 138.92 ÷ 7.15 = 19.44

5 Click competitor name to see calculations.

Valuation ratio Description The company
P/E ratio The P/E ratio tells analyst how much an investor in common stock pays per dollar of current earnings. AbbVie Inc. P/E ratio decreased from Q4 2021 to Q1 2022 and from Q1 2022 to Q2 2022.

Price to Operating Profit (P/OP)

AbbVie Inc., historical P/OP calculation (quarterly data)

Microsoft Excel
Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017
No. shares of common stock outstanding1 1,768,096,495 1,767,110,083 1,768,753,829 1,767,880,465 1,767,175,532 1,766,222,336 1,765,881,690 1,765,473,923 1,764,833,246 1,476,742,215 1,479,156,683 1,478,821,109 1,478,483,838 1,478,332,177 1,475,083,514 1,504,216,327 1,514,272,698 1,586,879,451 1,587,972,655 1,596,429,740 1,594,094,698 1,591,540,513
Selected Financial Data (US$)
Operating earnings (in millions) 3,295  4,717  5,074  4,306  4,441  4,103  3,753  3,255  752  3,603  3,956  2,617  3,400  3,010  (2,441) 3,159  2,762  2,903  1,794  2,705  2,674  2,419 
Operating profit per share2 9.84 10.49 10.13 9.39 8.80 6.72 6.43 6.55 6.19 9.19 8.78 4.45 4.82 4.39 4.33 7.06 6.71 6.35 6.04 0.00 0.00 0.00
Share price1, 3 138.92 152.83 144.03 116.53 115.45 115.75 105.01 94.50 94.29 83.96 94.96 82.08 65.23 78.71 79.41 86.96 94.06 100.17 118.60 93.96 71.22 66.99
Valuation Ratio
P/OP ratio4 14.12 14.57 14.21 12.41 13.12 17.23 16.32 14.42 15.23 9.13 10.82 18.43 13.53 17.93 18.35 12.32 14.01 15.78 19.63
Benchmarks
P/OP Ratio, Competitors5
Amgen Inc. 14.08 15.88 16.24 16.73 17.48 15.26 14.96 13.82 15.84 14.22 13.84 12.52 11.35 10.73 11.46 12.13 12.16 11.45 12.71
Eli Lilly & Co. 39.20 36.49 35.70 37.21 42.01 31.17 32.66 22.98 25.58 24.82 27.08 23.37 23.99 38.43 33.99 37.45 47.62 25.86 39.61
Johnson & Johnson 20.45 21.06 18.68 18.99 20.14 21.12 21.84 19.46 19.66 18.67 19.83 17.23 19.08 20.36 18.34 20.42 18.93 18.18 18.94
Merck & Co. Inc. 11.72 14.29 15.39 30.71 38.03 30.14 23.89 16.00 17.23 15.88 17.47 17.97 18.21 19.17 25.08 25.60 34.95 27.63 22.58
Moderna Inc. 4.66 3.79 4.59 15.13 44.01 101.69
Pfizer Inc. 9.11 11.49 13.30 16.37 19.83 22.85 23.12 22.27 22.17 17.42 14.36 14.64 13.82 15.62 17.19 18.14 17.36 15.05 15.62
Regeneron Pharmaceuticals Inc. 9.68 7.98 7.55 9.32 9.65 13.32 14.82 20.36 23.98 26.60 19.01 16.21 15.41 14.44 17.53 16.43 18.75 14.23 16.71
Thermo Fisher Scientific Inc. 23.99 21.84 21.07 23.87 19.77 18.53 22.81 31.49 36.59 28.44 26.84 26.99 24.59 28.45 27.33 26.24 28.33 26.99 28.24

Based on: 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31).

1 Data adjusted for splits and stock dividends.

2 Q2 2022 Calculation
Operating profit per share = (Operating earningsQ2 2022 + Operating earningsQ1 2022 + Operating earningsQ4 2021 + Operating earningsQ3 2021) ÷ No. shares of common stock outstanding
= (3,295,000,000 + 4,717,000,000 + 5,074,000,000 + 4,306,000,000) ÷ 1,768,096,495 = 9.84

3 Closing price as at the filing date of AbbVie Inc. Quarterly or Annual Report.

4 Q2 2022 Calculation
P/OP ratio = Share price ÷ Operating profit per share
= 138.92 ÷ 9.84 = 14.12

5 Click competitor name to see calculations.

Valuation ratio Description The company
P/OP ratio Because P/E ratio is calculated using net income, the ratio can be sensitive to nonrecurring earnings and capital structure, analysts may use price to operating profit. AbbVie Inc. P/OP ratio increased from Q4 2021 to Q1 2022 but then decreased significantly from Q1 2022 to Q2 2022.

Price to Sales (P/S)

AbbVie Inc., historical P/S calculation (quarterly data)

Microsoft Excel
Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017
No. shares of common stock outstanding1 1,768,096,495 1,767,110,083 1,768,753,829 1,767,880,465 1,767,175,532 1,766,222,336 1,765,881,690 1,765,473,923 1,764,833,246 1,476,742,215 1,479,156,683 1,478,821,109 1,478,483,838 1,478,332,177 1,475,083,514 1,504,216,327 1,514,272,698 1,586,879,451 1,587,972,655 1,596,429,740 1,594,094,698 1,591,540,513
Selected Financial Data (US$)
Net revenues (in millions) 14,583  13,538  14,886  14,342  13,959  13,010  13,858  12,902  10,425  8,619  8,704  8,479  8,255  7,828  8,305  8,236  8,278  7,934  7,739  6,995  6,944  6,538 
Sales per share2 32.44 32.10 31.77 31.21 30.40 28.42 25.94 23.02 20.53 23.06 22.49 22.23 22.07 22.08 22.20 21.40 20.44 18.66 17.77 0.00 0.00 0.00
Share price1, 3 138.92 152.83 144.03 116.53 115.45 115.75 105.01 94.50 94.29 83.96 94.96 82.08 65.23 78.71 79.41 86.96 94.06 100.17 118.60 93.96 71.22 66.99
Valuation Ratio
P/S ratio4 4.28 4.76 4.53 3.73 3.80 4.07 4.05 4.10 4.59 3.64 4.22 3.69 2.96 3.56 3.58 4.06 4.60 5.37 6.67
Benchmarks
P/S Ratio, Competitors5
Amgen Inc. 5.35 5.21 5.10 5.04 5.37 5.68 5.64 5.33 6.30 5.96 6.03 5.61 5.00 4.78 5.22 5.56 5.65 5.27 5.82
Eli Lilly & Co. 9.99 9.47 8.01 8.62 9.16 6.88 8.06 5.41 6.26 6.36 6.03 4.67 4.67 4.80 5.15 4.62 4.34 3.85 3.71
Johnson & Johnson 4.80 5.00 4.66 4.69 5.08 5.09 5.15 4.73 4.84 4.78 4.79 4.16 4.32 4.62 4.45 4.61 4.36 4.29 4.56
Merck & Co. Inc. 3.87 4.12 3.96 4.32 4.05 4.23 3.93 4.30 4.38 4.05 4.33 4.59 4.87 4.67 4.92 4.57 4.29 3.75 3.68
Moderna Inc. 3.29 2.82 3.45 10.53 27.41 33.34 309.64
Pfizer Inc. 2.77 3.00 3.18 4.03 4.78 4.84 4.50 4.71 4.69 4.21 3.66 3.85 3.80 4.20 4.49 4.75 4.51 3.89 4.05
Regeneron Pharmaceuticals Inc. 4.66 4.40 4.20 5.14 5.20 5.78 6.24 7.62 8.31 8.10 5.34 4.79 4.56 5.11 6.62 6.08 6.92 5.20 5.92
Thermo Fisher Scientific Inc. 5.40 5.20 5.39 6.45 5.54 5.13 5.52 6.58 6.24 5.08 4.83 4.83 4.43 4.52 4.24 3.95 4.07 3.84 4.01

Based on: 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31).

1 Data adjusted for splits and stock dividends.

2 Q2 2022 Calculation
Sales per share = (Net revenuesQ2 2022 + Net revenuesQ1 2022 + Net revenuesQ4 2021 + Net revenuesQ3 2021) ÷ No. shares of common stock outstanding
= (14,583,000,000 + 13,538,000,000 + 14,886,000,000 + 14,342,000,000) ÷ 1,768,096,495 = 32.44

3 Closing price as at the filing date of AbbVie Inc. Quarterly or Annual Report.

4 Q2 2022 Calculation
P/S ratio = Share price ÷ Sales per share
= 138.92 ÷ 32.44 = 4.28

5 Click competitor name to see calculations.

Valuation ratio Description The company
P/S ratio An rationale for the P/S ratio is that sales, as the top line in an income statement, are generally less subject to distortion or manipulation than other fundamentals such as EPS or book value. Sales are also more stable than earnings and never negative. AbbVie Inc. P/S ratio increased from Q4 2021 to Q1 2022 but then decreased significantly from Q1 2022 to Q2 2022.

Price to Book Value (P/BV)

AbbVie Inc., historical P/BV calculation (quarterly data)

Microsoft Excel
Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017
No. shares of common stock outstanding1 1,768,096,495 1,767,110,083 1,768,753,829 1,767,880,465 1,767,175,532 1,766,222,336 1,765,881,690 1,765,473,923 1,764,833,246 1,476,742,215 1,479,156,683 1,478,821,109 1,478,483,838 1,478,332,177 1,475,083,514 1,504,216,327 1,514,272,698 1,586,879,451 1,587,972,655 1,596,429,740 1,594,094,698 1,591,540,513
Selected Financial Data (US$)
Stockholders’ equity (deficit) (in millions) 14,653  16,283  15,408  13,550  12,569  13,710  13,076  15,270  14,708  (7,415) (8,172) (8,226) (8,566) (7,826) (8,446) (2,921) (3,375) 3,553  5,097  6,687  6,009  4,998 
Book value per share (BVPS)2 8.29 9.21 8.71 7.66 7.11 7.76 7.40 8.65 8.33 -5.02 -5.52 -5.56 -5.79 -5.29 -5.73 -1.94 -2.23 2.24 3.21 4.19 3.77 3.14
Share price1, 3 138.92 152.83 144.03 116.53 115.45 115.75 105.01 94.50 94.29 83.96 94.96 82.08 65.23 78.71 79.41 86.96 94.06 100.17 118.60 93.96 71.22 66.99
Valuation Ratio
P/BV ratio4 16.76 16.59 16.53 15.20 16.23 14.91 14.18 10.93 11.31 44.74 36.95 22.43 18.89 21.33
Benchmarks
P/BV Ratio, Competitors5
Amgen Inc. 54.46 138.87 18.51 14.95 15.72 14.57 14.53 11.57 13.67 14.33 13.84 11.47 10.37 9.92 9.41 8.56 8.35 7.41 5.02 3.98 4.05 3.91
Eli Lilly & Co. 34.00 29.75 25.28 30.85 38.00 25.41 35.07 26.02 35.12 47.73 51.67 31.28 39.03 46.37 12.87 8.58 8.96 6.18 7.33 6.20 6.49 6.43
Johnson & Johnson 6.01 6.36 5.90 6.10 6.51 6.51 6.72 5.93 6.19 6.46 6.61 5.84 5.78 6.39 6.08 5.81 5.60 5.34 5.79 5.08 4.98 4.72
Merck & Co. Inc. 5.12 5.44 5.05 5.76 5.73 7.30 7.46 6.97 7.47 7.43 7.83 7.87 7.82 7.31 7.79 5.88 5.44 4.54 4.30 3.96 4.31 4.35
Moderna Inc. 4.06 3.61 4.31 11.37 25.06 16.79 24.16 9.67 9.88 12.03 8.21 4.29 3.25 5.29
Pfizer Inc. 3.21 3.37 3.35 3.69 3.78 3.27 2.98 3.10 3.31 3.16 3.00 3.14 3.42 3.84 3.80 3.55 3.44 2.80 2.98 3.45 3.41 3.37
Regeneron Pharmaceuticals Inc. 3.21 3.65 3.60 4.04 4.26 4.44 4.81 6.21 7.34 5.33 3.79 3.48 3.38 3.74 5.07 4.92 5.97 4.80 5.66 7.37 9.07 9.49
Thermo Fisher Scientific Inc. 5.47 5.23 5.18 6.51 5.75 5.25 5.15 5.89 5.48 4.56 4.16 4.15 3.83 4.02 3.75 3.51 3.55 3.24 3.30 3.14 3.07 3.07

Based on: 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31).

1 Data adjusted for splits and stock dividends.

2 Q2 2022 Calculation
BVPS = Stockholders’ equity (deficit) ÷ No. shares of common stock outstanding
= 14,653,000,000 ÷ 1,768,096,495 = 8.29

3 Closing price as at the filing date of AbbVie Inc. Quarterly or Annual Report.

4 Q2 2022 Calculation
P/BV ratio = Share price ÷ BVPS
= 138.92 ÷ 8.29 = 16.76

5 Click competitor name to see calculations.

Valuation ratio Description The company
P/BV ratio The P/BV ratio is interpreted as an indicator of market judgment about the relationship between a company required rate of return and its actual rate of return. AbbVie Inc. P/BV ratio increased from Q4 2021 to Q1 2022 and from Q1 2022 to Q2 2022.